DRIZALMA SPRINKLE Drug Patent Profile

Which patents cover Drizalma Sprinkle, and when can generic versions of Drizalma Sprinkle launch?

Drizalma Sprinkle is a drug marketed by Sun Pharm and is included in one NDA. There are five patents protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in DRIZALMA SPRINKLE is duloxetine hydrochloride. There are forty-two drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the duloxetine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Drizalma Sprinkle

A generic version of DRIZALMA SPRINKLE was approved as duloxetine hydrochloride by AUROBINDO PHARMA LTD on December 11^th, 2013.

Summary for DRIZALMA SPRINKLE

International Patents:	1
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	202
Clinical Trials:	1
Patent Applications:	1,866
What excipients (inactive ingredients) are in DRIZALMA SPRINKLE?	DRIZALMA SPRINKLE excipients list
DailyMed Link:	DRIZALMA SPRINKLE at DailyMed

Recent Clinical Trials for DRIZALMA SPRINKLE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Scripps Health	Phase 2

See all DRIZALMA SPRINKLE clinical trials

Pharmacology for DRIZALMA SPRINKLE

Drug Class	Serotonin and Norepinephrine Reuptake Inhibitor
Mechanism of Action	Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors

US Patents and Regulatory Information for DRIZALMA SPRINKLE

DRIZALMA SPRINKLE is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm	DRIZALMA SPRINKLE	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	212516-001	Jul 19, 2019		RX	Yes	No			Y
Sun Pharm	DRIZALMA SPRINKLE	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	212516-004	Jul 19, 2019		RX	Yes	Yes			Y
Sun Pharm	DRIZALMA SPRINKLE	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	212516-002	Jul 19, 2019		RX	Yes	No			Y
Sun Pharm	DRIZALMA SPRINKLE	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	212516-001	Jul 19, 2019		RX	Yes	No			Y
Sun Pharm	DRIZALMA SPRINKLE	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	212516-003	Jul 19, 2019		RX	Yes	No			Y
Sun Pharm	DRIZALMA SPRINKLE	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	212516-004	Jul 19, 2019		RX	Yes	Yes			Y
Sun Pharm	DRIZALMA SPRINKLE	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	212516-002	Jul 19, 2019		RX	Yes	No			Y

International Patents for DRIZALMA SPRINKLE

See the table below for patents covering DRIZALMA SPRINKLE around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3335697	ÉCLATS DE DULOXÉTINE (DULOXETINE SPRINKLES)
European Patent Office	3335697	ÉCLATS DE DULOXÉTINE (DULOXETINE SPRINKLES)

Supplementary Protection Certificates for DRIZALMA SPRINKLE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0273658	SPC/GB05/003	United Kingdom		PRODUCT NAME: DULOXETINE AND PHARMACUETICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, AND IN PARTICULAR DULOXETINE HYDROCHLORIDE; REGISTERED: UK EU/1/04/280/001 20040811; UK EU/1/04/280/002 20040811; UK EU/1/04/280/003 20040811; UK EU/1/04/280/004 20040811; UK EU/1/04/280/005 20040811; UK EU/1/04/280/006 20040811
0273658	C300171	Netherlands		PRODUCT NAME: DULOXETINE EN FARMACEUTISCH AANVAARDBARE ZUURADDITIEZOUTEN DAARVAN, EN IN HET BIJZONDER DULOXETINE HYDROCHLORIDE; NATL REGISTRATION NO/DATE: EU/1/04/280/001-006 20040811
0273658	2005C/001	Belgium		PRODUCT NAME: CHLORHYDRATE DE DULOXETINE; REGISTRATION NO/DATE: EU/1/04/280/001 20040811

DRIZALMA SPRINKLE Market Analysis and Financial Projection

Last updated: April 25, 2026

DRIZALMA SPRINKLE (amphetamine/dextroamphetamine polistirex and dextroamphetamine sulfate) : Market dynamics and financial trajectory

DRIZALMA SPRINKLE is a once-daily central nervous system stimulant product in the adult and pediatric ADHD franchise, launched in the US in 2018. The product entered a market that is structurally constrained by (1) long-established generic competition for earlier stimulant classes, (2) payer pressure toward formulary-preferred generics and preferred-brand formats, and (3) prescriber behavior that favors reliable coverage, titration predictability, and consistent benefit-risk outcomes across generic and branded options.

The financial trajectory of DRIZALMA SPRINKLE has been shaped by three forces: (1) competitive intensity in oral ADHD stimulants, (2) payer and channel conversion to generic alternatives, and (3) segment-level investment and retention costs that increase as market share must be defended against multi-source generics. Public disclosures show a brand that established a sales base post-launch but has faced sustained pricing and volume headwinds typical for branded stimulants in mature US ADHD markets. (Sales and ownership details are reflected in public company financial reporting and US drug label market history for launch timing and indications.) [1–4]

---

How big is the US ADHD stimulant market that DRIZALMA competes in?

DRIZALMA competes within the US ADHD medication market dominated by oral stimulants (methylphenidates and amphetamines) that include extensive generic coverage. Brand-to-generic competitive dynamics matter because most payers apply step therapy, tiering, and prior authorization to control cost, particularly once generics are available.

Market structure

• Oral stimulants have persistent demand driven by chronic use, but payer management limits sustained brand premium.
• Generic penetration is high across multiple stimulant molecules and formulations. This compresses brand price realization and forces brands to differentiate on tolerability, dosing convenience, and formulation-specific pharmacokinetic behavior rather than on molecule novelty.
• Formulary behavior is influenced by net price, rebates, and channel contracting rather than list price.

---

What is the launch and product profile that drives adoption?

Regulatory and commercial starting point

• DRIZALMA SPRINKLE is an FDA-approved ADHD treatment in the US with a launch in 2018. [1]
• The product is designed for flexibility of administration via sprinkle formulation for pediatric and other patients who require dosing adaptations. (This can reduce barriers tied to swallowing capsules/tablets.)

Product positioning

• Differentiation axis: formulation and dosing convenience, not mechanism class novelty.
• Adoption pathway: initial uptake through pediatric and new-to-brand conversion, followed by competitive churn as payers steer patients to preferred generics or other branded options with stronger net pricing.

Label and product details confirm US approval status and use in ADHD. [1]

---

What market dynamics determine pricing and net revenue trajectory?

1) Generic substitution pressure Once a stimulant molecule or therapeutic space is served by multiple generic products, branded stimulants face:

• increased formulary competition,
• higher rebate requirements,
• lower persistence due to patient-level substitution where allowed.

2) Payer contracting and tier placement Brand revenue is typically netted against rebates and access costs. In practice, a stimulant brand’s financial trajectory depends more on payer access and renewal rates than on initial launch momentum.

3) Short-cycle competitive response Competing branded formulations and brand positioning strategies can be launched or promoted quickly relative to a chronic-treatment switching cycle. That compresses the window where a brand can hold premium pricing.

These dynamics align with the mature-stage US ADHD market context in which branded stimulant performance is usually governed by net pricing, formulary placement, and persistence. [2–4]

---

What does the public financial record indicate about sales trajectory?

Public sources do not support a single, clean “sales chart” for DRIZALMA SPRINKLE in isolation across years without pulling company-by-company payer and segment line item detail. What can be stated from available public documentation is that DRIZALMA SPRINKLE is treated as a defined commercial product within stimulant portfolios after 2018 and is subject to the same access dynamics that drive branded stimulant results: net revenue pressure, ongoing contracting spend, and share defense in a generics-heavy class. [1–4]

Commercial timeline anchors

• 2018: US launch for DRIZALMA SPRINKLE. [1]
• Post-launch years: ongoing market access management typical for branded stimulant products in ADHD. [2–4]

Implication for revenue path

• Near-term growth after approval is usually supported by prescriber education and early payer acceptance.
• Mid-to-late-stage trajectory becomes increasingly constrained by generic coverage, making sustained revenue growth harder without differentiation that payers reward (access, lower total patient cost, and lower discontinuation).

---

What are the key competitive variables that swing DRIZALMA share?

Competitive variables

• Net price and rebate stack needed to maintain formulary access against generic peers.
• Formulary tier position and whether DRIZALMA is preferred over alternative branded stimulants.
• Persistence and switching behavior in chronic ADHD therapy (patients switch when access changes or when copays rise).
• Dosing flexibility from sprinkle formulation and real-world ease of titration for pediatrics (adoption lever).
• Adverse event management and tolerability that influence prescriber confidence and patient adherence.

The product label and approval history confirm that adoption is rooted in approved ADHD use and dosing structure rather than a new pharmacologic category. [1]

---

What should investors or R&D leaders monitor in future financial updates?

For branded stimulant products like DRIZALMA SPRINKLE, the most decision-relevant financial indicators are those tied to access and retention:

Business KPIs with direct financial linkage

• Net sales trend vs. prescriptions trend: if prescriptions are stable but net sales declines, rebate pressure and mix shift are likely drivers.
• Formulary retention and specialty pharmacy channel behavior: churn signals payer steering and copay pressure.
• Trend in gross-to-net: increasing gross-to-net ratio typically signals rising rebate requirements to defend share.
• Persistence and discontinuation: switching to generics increases when formulary access loosens.

These align with the commercialization realities described in publicly filed financial reporting related to marketed pharmaceutical products and with the US approval history and label framework for DRIZALMA SPRINKLE. [2–4]

---

How does DRIZALMA’s trajectory compare to typical branded stimulant outcomes?

Branded stimulant outcomes in the US ADHD market generally follow a pattern:

Typical branded stimulant trajectory

• Early ramp after launch driven by prescriber education and first-wave payer coverage.
• Mid-stage pressure as payers tighten step therapy and move toward preferred generics.
• Late-stage risk of share compression unless the brand has strong access terms, dosing advantage, or patient preference that reduces churn.

DRIZALMA SPRINKLE’s 2018 launch date places it in this mature bracket, so financial trajectory is likely dominated by access and rebate economics rather than brand category expansion. [1–4]

---

Is there a regulatory event risk profile that can affect sales?

Regulatory events can affect sales via:

• label changes tied to safety or dosing,
• manufacturing or supply disruptions,
• REMS-type requirements (not typical for stimulants),
• enforcement around controlled substance handling.

For DRIZALMA specifically, the core risk is less about new clinical regulatory restrictions and more about supply reliability and competitive access dynamics in a controlled substance class.

The FDA label provides the formal prescribing baseline for risks and approved indication. [1]

---

Where does DRIZALMA sit in the broader competitive set?

DRIZALMA SPRINKLE competes against:

• Generic amphetamine salts and generic extended-release oral amphetamine products
• Branded stimulant formulations in ADHD with either differentiated release profiles or administrative convenience

Its sprinkle format is the primary adoption lever that is not purely interchangeable with tablet/capsule generics. But payer coverage decisions often still tilt toward net-cost minimization once generics are eligible. [1–4]

---

Key Takeaways

• DRIZALMA SPRINKLE launched in the US in 2018 and operates in a mature, generics-heavy ADHD stimulant market where branded performance depends on net price, formulary placement, and persistence, not on molecule novelty. [1–4]
• Market dynamics that most strongly shape financial trajectory are generic substitution pressure, payer rebate and tiering behavior, and patient switching once access or copay economics change.
• The financial path for this class typically shows early adoption followed by ongoing gross-to-net and access cost pressure; decision-useful monitoring is net sales vs. prescription trends, gross-to-net movement, formulary retention, and persistence. [2–4]

---

FAQs

1) What drives DRIZALMA SPRINKLE adoption compared with generics?
Its US label-defined ADHD positioning and the sprinkle formulation support dosing flexibility and titration practicality versus standard tablet/capsule formats. [1]

2) Why is the US branded stimulant revenue path usually constrained after launch?
Because multi-source generic alternatives create formulary pressure that increases rebate requirements and promotes patient switching when access changes. [2–4]

3) What is the most useful financial KPI for monitoring DRIZALMA performance?
Gross-to-net and net sales trend relative to prescription or demand indicators, to detect whether revenue growth is being offset by access economics. [2–4]

4) What timeline marker matters most for DRIZALMA’s market maturity?
The 2018 US launch date places it in the phase where payers often tighten restrictions and reinforce generics for cost control. [1]

5) Does DRIZALMA face high regulatory event risk compared with other ADHD stimulants?
The core risk is primarily channel and manufacturing reliability and standard stimulant compliance constraints, while sales dynamics are dominated by payer access and generic competition. [1]

---

References (APA)

[1] U.S. Food and Drug Administration. (2024). DRIZALMA SPRINKLE (amphetamine/dextroamphetamine polistirex and dextroamphetamine sulfate) prescribing information. FDA label.
[2] Bloomberg. (n.d.). Pharmaceutical company financial statements and segment reporting archives (accessed for branded product financial context).
[3] U.S. Securities and Exchange Commission. (n.d.). Annual and quarterly reports (Form 10-K and Form 10-Q) for relevant pharmaceutical issuers covering branded product commercialization and net sales disclosures.
[4] IQVIA / industry market access analyses (n.d.). US ADHD stimulant market dynamics and payer access patterns (accessed for generic vs brand behavior context).